We have made significant progress in the treatment of patients with mutations in the Epidermal Growth Factor Receptor (EGFR) and rearrangements involving anaplastic lymphoma kinase (ALK).
其中，我们对于发生表皮生长因子受体（EGFR）突变和间变淋巴瘤激酶（ALK）重排的非小细胞肺癌患者的治疗取得了显著的进展。
We have made significant progress in the treatment of patients with mutations in the Epidermal Growth Factor Receptor (EGFR) and rearrangements involving anaplastic lymphoma kinase (ALK).
其中，我们对于发生表皮生长因子受体（EGFR）突变和间变淋巴瘤激酶（ALK）重排的非小细胞肺癌患者的治疗取得了显著的进展。
应用推荐